This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

~Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT06789913

Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)

The purpose of this study is to develop a standardized assessment for patients treated for venous malformations (VM). Venous malformations result from the abn…

Vascular MalformationsVM - Vascular Malformation

~Estimated

~$10 – $750

Johns Hopkins UniversityNCT04104464

Identification of Biomarkers for Patients with Vascular Anomalies

The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest pr…

Vascular AnomalyGeneralized Lymphatic AnomalyKaposiform Hemangioendothelioma+4 more

~Estimated

~$10 – $675

Children's Hospital Medical Center, CincinnatiNCT03001180